TSX runs higher on rate cut expectations
Investing.com -- Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) stock rose 4.4% after the U.S. Food and Drug Administration (FDA) approved its COVID-19 vaccine, Spikevax, for children aged 6 months through 11 years who are at increased risk for COVID-19 disease.
The approval represents a significant regulatory milestone for the company, as the vaccine was previously only available to this pediatric population under Emergency Use Authorization (EUA). The full approval expands Moderna’s market reach to vulnerable younger populations.
"COVID-19 continues to pose a significant potential threat to children, especially those with underlying medical conditions. Vaccination can be an important tool for protecting our youngest against severe disease and hospitalization," said Stéphane Bancel, Chief Executive Officer of Moderna.
The company expects to have its updated Spikevax vaccine available for eligible populations in the U.S. for the 2025-2026 respiratory virus season.
Brookline Capital Markets analyst Leah Rush Cann reiterated a Buy rating and $198.00 price target on Moderna (NASDAQ:MRNA), saying, "We currently estimate that 2025 Moderna COVID-19 vaccine sales will include 10.9 million doses in the US, compared to an estimated 14.6 million in 2024. We estimate COVID-19 vaccines could have 2025 global sales of $2.4 billion, and grow to 2030 sales of $15.6 billion."
The FDA’s decision comes as health authorities continue to emphasize the importance of COVID-19 vaccination, particularly for high-risk individuals across all age groups.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.